Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours

Journal of Oral Pathology and Medicine

Volumn 38, Issue 6, 2009, Pages 508-513

  Monteiro, L S ^a,b,f   Bento, M J ^c   Palmeira, C ^c,d   Lopes, C ^e  

^a Higher Institute of Health Sciences (ISCSN)   (Portugal)

^b Dental Sciences Group   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

^f UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Anti EGFR therapy; EGFR; Immnunohistochemistry; Salivary gland cancers

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMA, PLEOMORPHIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, ACINAR CELL; CARCINOMA, ADENOID CYSTIC; CARCINOMA, DUCTAL; CARCINOMA, MUCOEPIDERMOID; CELL MEMBRANE; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PAROTID NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS, MINOR; SURVIVAL RATE; YOUNG ADULT;

EID: 67650757305     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00770.x     Document Type: Article

References (27)

1. Kokemueller H, Swennen G, Brueggemann N, Brachvogel P, Eckardt A, Hausamen JE. Epithelial malignancies of the salivary glands: clinical experience of a single institution - a review. Int J Oral Maxillofac Surg 2004 33 : 423 32.
2. Ellis GL, Auclair PL. Tumors of the salivary glands. Atlas of tumor pathology, 3rd series. Washington, DC : Armed Forces Institute of Pathology, 1995.
3. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005 103 : 2435 46.
4. O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA. C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 2002 38 : 73 80. (Pubitemid 34076575)
5. Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003 3 : 367 80.
6. Katopodi E, Patsouris E, Papanikolaou V, Karameris A, Douzinas E, Papanicolaou S. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 95 : 266 8.
7. Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular target therapy. Oral Oncol 2007 43 : 729 34.
8. Barnes L, Everson JW, Reichart P, Sidransky D. World health organization classification of tumours: pathology and genetics of head and neck tumours. Lyon, France : IARC Press, 2005.
9. American Joint Committee on Cancer (AJCC). Cancer Staging Handbook. Classification of malignant tumors, 6th edn. New York : Springer, 2002 : 27 87
10. Sutton DN, Brown JS, Rogers SN, Vaughan JA, Woolgar JA. The prognostic implications of the surgical margin in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2003 32 : 30 4.
11. Diniz-Freitas M, García-Caballero T, Antúnez-López J, Gándara-Rey JM, García-García A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 2007 13 : 285 90.
12. Sorensen KB, Godballe C, Stricker K, Krogdahl A. Parotid Carcinoma: expression of Kit protein and epidermal growth factor receptor. J Oral Pathol Med 2006 35 : 286 91.
13. Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 2001 111 : 1373 8.
14. Fan CY, Melhem MF, Hosal AS, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor α in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001 127 : 1075 9.
15. Shang J, Shui Y, Sheng L, Wang K, Hu Q, Wei Q. Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for target therapy. Oncol Rep 2008 19 : 435 40.
16. Shintani S, Funayama T, Yoshihama Y, et al. Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res 1995 15 : 2623 6.
17. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002 24 : 632 6.
18. Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A, Feinmesser R. Expression of EGFR and CerbB-2 as prognostic factors in cancer of the tongue. Oral Oncol 2004 40 : 532 7.
19. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. Br J Cancer 2003 89 : 681 6.
20. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008 53 : 567 77.
21. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998 90 : 824 32.
22. Schartinger VL, Kacani L, Ardle J, et al. Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2004 66 : 21 6.
23. Maiorano E, Favia G, Maisonnneuve P, Viale G. Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J Pathol 1998 185 : 167 74.
24. Dahse R, Kosmehl H. Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 2008 99 : 90 2.
25. Choy H. The emerging role of epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004 59 : 1.
26. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of glands. J Clin Oncol 2007 25 : 3978 84.
27. Yournes MN, Yazici YD, Gu M, et al. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 2006 5 : 2696 705.